South San Francisco-based Catalyst Biosciences, which has kept a low profile in recent years, has jumped back into the spotlight with a reverse merger with Targacept, the beleaguered North Carolina biotech that suffered a long string of embarrassing failures in the clinic.
Pfizer's Prevenar 13 is already the world's best-selling vaccine, and it kept on rolling Tuesday with a European label expansion.
Western drugmakers finding their way into the Middle East and North Africa are being met by some domestic companies expanding operations in an effort to take on this competition. Among those is MS Pharma, which is now expanding manufacturing in Jordan with a loan from the European Bank for Reconstruction and Development.
There's a reason immuno-oncology is among the hottest fields in biopharma today--and that's the $20 billion or so in 2022 sales that many analysts estimate. No wonder Bristol-Myers Squibb, Merck, AstraZeneca and Roche are speeding ahead with their research in the field, with Sanofi, Novartis and Pfizer racing to catch up.
Seventy percent of the 20 best-selling drugs in Taiwan are for treating blood pressure, strokes and other chronic diseases.
Several years ago, Pfizer added California-based Alacer to its consumer health business. But now it has decided it doesn't need a plant in California that came with that deal and will close it in May, laying off the 70 workers there.
Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.
Pfizer has updated the risk factors section of its U.S. Securities and Exchange Commission (SEC) filings to reflect the new normal in cybersecurity. The Big Pharma lays out the situation plainly: "As a global pharmaceutical company, our systems are subject to frequent attacks."
Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like.
Here is part two of comments from C-suite execs on emerging markets and Asia in the latest quarterly conference calls.